137 related articles for article (PubMed ID: 23400813)
1. Glutathione modified CdTe quantum dots as a label for studying DNA interactions with platinum based cytostatics.
Ryvolova M; Smerkova K; Chomoucka J; Hubalek J; Adam V; Kizek R
Electrophoresis; 2013 Mar; 34(6):801-8. PubMed ID: 23400813
[TBL] [Abstract][Full Text] [Related]
2. DNA interaction with platinum-based cytostatics revealed by DNA sequencing.
Smerkova K; Vaculovic T; Vaculovicova M; Kynicky J; Brtnicky M; Eckschlager T; Stiborova M; Hubalek J; Adam V
Anal Biochem; 2017 Dec; 539():22-28. PubMed ID: 28970072
[TBL] [Abstract][Full Text] [Related]
3. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
Mandal R; Kalke R; Li XF
Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
[TBL] [Abstract][Full Text] [Related]
4. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
5. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.
Saris CP; van de Vaart PJ; Rietbroek RC; Blommaert FA
Carcinogenesis; 1996 Dec; 17(12):2763-9. PubMed ID: 9006117
[TBL] [Abstract][Full Text] [Related]
6. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
7. Presence of cancerostatic platinum compounds in hospital wastewater and possible elimination by adsorption to activated sludge.
Lenz K; Hann S; Koellensperger G; Stefanka Z; Stingeder G; Weissenbacher N; Mahnik SN; Fuerhacker M
Sci Total Environ; 2005 Jun; 345(1-3):141-52. PubMed ID: 15919535
[TBL] [Abstract][Full Text] [Related]
8. "Turn off-on" fluorescent sensor for platinum drugs-DNA interactions based on quantum dots.
Zhao D; Li J; Yang T; He Z
Biosens Bioelectron; 2014 Feb; 52():29-35. PubMed ID: 24016536
[TBL] [Abstract][Full Text] [Related]
9. Kinetic study on the reactions of platinum drugs with glutathione.
Hagrman D; Goodisman J; Souid AK
J Pharmacol Exp Ther; 2004 Feb; 308(2):658-66. PubMed ID: 14610218
[TBL] [Abstract][Full Text] [Related]
10. Quality control of pharmaceutical formulations containing cisplatin, carboplatin, and oxaliplatin by micellar and microemulsion electrokinetic chromatography (MEKC, MEEKC).
Nussbaumer S; Fleury-Souverain S; Schappler J; Rudaz S; Veuthey JL; Bonnabry P
J Pharm Biomed Anal; 2011 May; 55(2):253-8. PubMed ID: 21330090
[TBL] [Abstract][Full Text] [Related]
11. Protein interactions with platinum-DNA adducts: from structure to function.
Chaney SG; Campbell SL; Temple B; Bassett E; Wu Y; Faldu M
J Inorg Biochem; 2004 Oct; 98(10):1551-9. PubMed ID: 15458816
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, oxaliplatin, and carboplatin unequally inhibit in vitro mRNA translation.
Becker JP; Weiss J; Theile D
Toxicol Lett; 2014 Feb; 225(1):43-7. PubMed ID: 24275384
[TBL] [Abstract][Full Text] [Related]
14. Separation and identification of platinum adducts with DNA nucleotides by capillary zone electrophoresis and capillary zone electrophoresis coupled to mass spectrometry.
Warnke U; Gysler J; Hofte B; Tjaden UR; van der Greef J; Kloft C; Schunack W; Jaehde U
Electrophoresis; 2001 Jan; 22(1):97-103. PubMed ID: 11197185
[TBL] [Abstract][Full Text] [Related]
15. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.
Chaney SG; Campbell SL; Bassett E; Wu Y
Crit Rev Oncol Hematol; 2005 Jan; 53(1):3-11. PubMed ID: 15607931
[TBL] [Abstract][Full Text] [Related]
16. New insights into the mechanism underlying the synergistic action of ionizing radiation with platinum chemotherapeutic drugs: the role of low-energy electrons.
Rezaee M; Hunting DJ; Sanche L
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):847-53. PubMed ID: 23910707
[TBL] [Abstract][Full Text] [Related]
17. [Quantitative determination of pazufloxacin using water-soluble quantum dots as fluorescent probes].
Ling X; Deng DW; Zhong WY; Yu JS
Guang Pu Xue Yu Guang Pu Fen Xi; 2008 Jun; 28(6):1317-21. PubMed ID: 18800713
[TBL] [Abstract][Full Text] [Related]
18. Exploring binding affinity of oxaliplatin and carboplatin, to nucleoprotein structure of chromatin: spectroscopic study and histone proteins as a target.
Soori H; Rabbani-Chadegani A; Davoodi J
Eur J Med Chem; 2015 Jan; 89():844-50. PubMed ID: 25462284
[TBL] [Abstract][Full Text] [Related]
19. Human serum albumin interaction with oxaliplatin studied by capillary isoelectric focusing with the whole column imaging detection and spectroscopic method.
Lemma T; Pawliszyn J
J Pharm Biomed Anal; 2009 Nov; 50(4):570-5. PubMed ID: 19070448
[TBL] [Abstract][Full Text] [Related]
20. Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro.
Bassett E; Vaisman A; Havener JM; Masutani C; Hanaoka F; Chaney SG
Biochemistry; 2003 Dec; 42(48):14197-206. PubMed ID: 14640687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
